Cite
HARVARD Citation
Rathkopf, D. et al. (2015). Everolimus combined with gefitinib in patients with metastatic castration‐resistant prostate cancer: Phase 1/2 results and signaling pathway implications. Cancer. 121 (21), pp. 3853-3861. [Online].